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Abstract
Background: To improve cancer therapy, it is critical to target metastasizing cells. Circulating tumor cells (CTCs) are rare cells
found in the blood of patients with solid tumors and may play a key role in cancer dissemination. Uncovering CTC
phenotypes offers a potential avenue to inform treatment. However, CTC transcriptional profiling is limited by leukocyte
contamination; an approach to surmount this problem is single cell analysis. Here we demonstrate feasibility of performing
high dimensional single CTC profiling, providing early insight into CTC heterogeneity and allowing comparisons to breast
cancer cell lines widely used for drug discovery.
Methodology/Principal Findings: We purified CTCs using the MagSweeper, an immunomagnetic enrichment device that
isolates live tumor cells from unfractionated blood. CTCs that met stringent criteria for further analysis were obtained from
70% (14/20) of primary and 70% (21/30) of metastatic breast cancer patients; none were captured from patients with non-
epithelial cancer (n=20) or healthy subjects (n=25). Microfluidic-based single cell transcriptional profiling of 87 cancer-
associated and reference genes showed heterogeneity among individual CTCs, separating them into two major subgroups,
based on 31 highly expressed genes. In contrast, single cells from seven breast cancer cell lines were tightly clustered
together by sample ID and ER status. CTC profiles were distinct from those of cancer cell lines, questioning the suitability of
such lines for drug discovery efforts for late stage cancer therapy.
Conclusions/Significance: For the first time, we directly measured high dimensional gene expression in individual CTCs
without the common practice of pooling such cells. Elevated transcript levels of genes associated with metastasis NPTN,
S100A4, S100A9, and with epithelial mesenchymal transition: VIM, TGFß1, ZEB2, FOXC1, CXCR4, were striking compared to cell
lines. Our findings demonstrate that profiling CTCs on a cell-by-cell basis is possible and may facilitate the application of
‘liquid biopsies’ to better model drug discovery.
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To cure epithelial-based cancers–such as cancers of the breast,
prostate, lung, colon, and pancreas–therapies need to be directed
toward those cells that cause metastases. Lethal epithelial cancers
generallyoriginateinaprimarytumorand thenspread(metastasize)
to other organs by shedding cells into the bloodstream and/or
lymphatic channels. Disseminating metastatic cells may lodge,
remain dormant for varying amounts of time, and ultimately grow
as secondary tumors in other body sites. Secondary tumors may re-
seed additional metastatic cells into the bloodstream [1,2], causing
subsequent tumor spread that result in multiple metastatic tumors
within the same organ and colonization of tumor cells in additional
organs, generally leading to patient demise.
While considerable progress has been made towards elucidating
the basic biology of primary tumors to guide therapy, the
molecular characterization of metastatic disease, which generally
occurs months or years after primary tumor excision, remains
limited. The treatment of patients with metastatic disease
continues to be based largely on biomarkers from their primary
tumor, despite frequent discordance between primary and
metastatic cancer [3,4]. Some patients with disseminated disease
may undergo biopsy of a single metastatic focus even though
multiple foci are concurrently present. However, as the majority of
metastatic lesions are never biopsied due to anatomic inaccessi-
bility or associated morbidity of the procedure, they are
unavailable for biological characterization. On the other hand,
CTCs offer a readily accessible means of studying the biology of
metastatic cells throughout the course of disease [5,6], and are
often referred to as a ‘‘liquid biopsy’’ [7].
CTCs are rare epithelial cells present in cancer patient blood
amidst approximately 5610
9 anuclear red blood cells and 5–
10610
6 nucleated white blood cells (leukocytes) per ml. Due to the
general absence of epithelial cells in normal blood, the standard
definition of a CTC is an epithelial cell found in the blood of a
patient with cancer, confirmed by 1) visualization of an intact
nucleus using DAPI, 49,6-diamidino-2-phenylindole, a DNA-
binding fluorescent stain; 2) expression of cytokeratin; and 3) lack
of expression of the white blood cell marker, CD45, the leukocyte-
common antigen gene [6,8].
According to the current standard of care, which includes
surgical resection of primary tumors, CTCs identifiable in the
blood of patients with metastatic recurrence must, by definition,
derive from metastatic foci. The number of CTCs in blood
samples has been shown to correlate with clinical outcome in
patients with metastatic breast, prostate, colorectal, and lung
cancer [9–13]. Additional biological characterization of CTCs is
confounded by significant leukocyte contamination or limited
methodological sensitivity, thereby requiring sample pooling
[14,15]. To address this, we developed an immunomagnetic
separation technology, the MagSweeper, that gently extracts live
CTCs with high purity from unfixed, unfractionated blood, and
facilitates robust analyses at the single cell level [16,17].
Intratumoral heterogeneity of primary breast cancers is well
illustrated by the presence of distinct oncogene mutations even
within a single microscopic field of tumor tissue [4]. Such
heterogeneity likely extends across the qualitative and/or quan-
titative expression of a multitude of genes resulting in distinctive
molecular phenotypes of clonal metastatic lesions at different
organ sites [18]. To prove the feasibility of high dimensional single
cell analysis of CTCs and explore the magnitude of CTC
heterogeneity across genes commonly known to be associated
with breast cancer phenotypes, we transcriptionally profiled single
CTCs isolated by the MagSweeper. We identified 2 major CTC
subgroups in patients with primary and metastatic breast cancer.
CTC subgroups appeared to cluster independently of established
biomarkers observed in the primary tumor, such as ER, PR, and
HER2 status. Heterogeneity among CTCs was significant, and
cell-to-cell variations occurred even within a single blood draw.
Our finding of CTC variability is consistent with primary and
metastatic tumor heterogeneity and suggests that single cell
phenotyping of CTCs is a practical approach to exploit this
variability for the effective implementation of molecular guided
cancer therapy on a more comprehensive scale than possible with
mutational analysis of a few known genes.
Materials and Methods
Ethics Statement
This study was reviewed and approved by Stanford’s Human
Subjects Research Compliance Board and adhered to HIPAA
regulations. All human subjects signed informed consent prior to
blood sample collection.
Cell Culture
MCF7, SKBR3, T47D and MDA-MB-231 breast cancer cell
lines were purchased from American Type Culture Collection
(ATCC) and tested to be free of mycoplasma contamination. Since
these cell lines were originally derived from disseminated lesions of
the human host (www.atcc.org), they are designated as ‘metastat-
ic’. Cells were cultured in Dulbecco’s Modified Eagle Medium
high glucose supplemented with 10% fetal bovine serum (FBS) and
100 units per ml of Penicillin-Streptomycin (Invitrogen) and grown
at 37uC and 5% CO2 in a humidified atmosphere. In addition,
well-characterized, novel cell lines - CCdl054, CCdl672, CCdl675,
previously developed from clinical primary breast tumor samples
[19–21], were included in this study. Primary tumor cell lines were
propagated in MCDB170 growth medium supplemented with 2%
FBS as described earlier [22].
Patient Samples
Study participants with primary and metastatic breast cancer
were recruited through the Stanford Breast Oncology Clinic at the
discretion of their treating medical oncologists. Blood was collected
by venipuncture or from implanted venous access ports or both
into 10 mL BD Vacutainer plastic EDTA tubes (Becton Dick-
inson). The first 9 ml tube of blood from each blood draw was
discarded to prevent contamination by skin epithelial cells from
the needle puncture site. Then, approximately 9 ml of blood was
collected from each human subject and kept at room temperature.
All blood samples were processed within three hours of collection.
Circulating Tumor Cell Isolation using MagSweeper
To isolate CTCs, whole blood was labeled with 4.5 mm magnetic
beads (Dynabeads Epithelial Enrich, Invitrogen) coated with the
monoclonal BerEP4 antibody against human EpCAM (epithelial
cell adhesion molecule, formally known as TACSTD1). Cells were
labeled at room temperature with constant mixing for one hour.
The samples were then diluted with PBS and processed for capture
by a sweeping magnetic device - the MagSweeper (Figures 1A &
1B). Two rounds of capture-wash-release were performed for all
studies, whereby the movement of the magnet produced a
controlled shear force that released many non-specifically bound
leukocytes and other blood cells (Figure 1C). Captured cells were
released into fresh buffer, then visually identified and photographed
using an Axio Observer A1 inverted microscope (Carl Zeiss). Single
cells were manually aspirated under visual guidance into a 1 ml
volume using a Pipetman P2 (Gilson) (Figure 1D). The captured
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(Applied Biosystems/Ambion) and frozen on dry ice. Individual
CTCs were stored at -80uC until analyzed.
Preamplification
Single tumor cells contain picogram quantities of RNA,
insufficient for reproducible whole genome microarray analysis.
Target genes were preamplified using TaqMan gene expression
assays (20x) (Applied Biosystems) and CellsDirect qRT-PCR kit
(Invitrogen). The TaqMan gene expression assays (20x) were
combined and diluted with TE (Tris and EDTA) buffer to yield
0.2x assay mixture. The pre-amplification was done in a 10 ml
volume including 5.0 ml Cells Direct 2x Reaction Mix; 2.5 ml
combined assay mixture, 1 ml of PBS containing the target cell [or
human reference RNA (Stratagene)], 0.5 ml TE (pH 8.0), and 1 ml
RT-Taq enzyme. The RT step was performed at 50uC for 15
minutes, followed by 18 cycles of amplification (95uC for 15
seconds and then 60uC for 4 minutes). Pre-amplified cDNA were
diluted 5 times in TE buffer and stored at 220uC.
Microfluidic Dynamic Arrays
TaqMan Universal Master Mix (Applied Biosystems) and 96.96
dynamic array chips, together with the NanoFlexTM 4-IFC
Controller and the BioMark Real –Time PCR System (Fluidigm
Corporation) were used for chip based high throughput qRT-PCR
arrays, performed following the standard Fluidigm protocol
[23,24]. The chip was first primed with Krytox in the IFC
Controller. Then, 5 ml sample mixtures containing 2.5m l2 x
TaqMan Universal Master Mix, 0.25 ml DA sample loading
reagent (Fluidigm Corporation), and 2.25 ml preamplified cDNA
were pipetted into the sample inlets. 5 ml assay mix containing
2.5 ml 20x TaqMan gene expression assay mix (Applied Biosys-
tems) and 2.5 ml DA Assay loading reagent (Fluidigm Corporation)
were pipetted into the assay inlets. The chip was then loaded and
mixed in the IFC Controller. qRT-PCR reactions of the chip were
performed using the BioMark Real-Time PCR System. The
cycling program consisted of 10 min at 95uC followed by 40 cycles
of 95uC for 15 sec and 60uC for 1 min.
Data Analyses
CT readings with Biomark software’s quality check score ,0.65
or CT $35 were treated as missing/immeasurable; otherwise, we
considered the gene expressed. The following ten genes were
excluded because: 1) HGF, RPS11, RPS18, and RPS27A primer sets
were not used on every chip; or 2), BMI1, EIF4E, EIF4EBP1,
MED1, POU5F1 (OCT4), and RPLPO produced false positives on
at least one chip, showing amplification in non-template control
Figure 1. MagSweeper instrumentation, and cell isolation steps. A. MagSweeper device showing magnetic rods sheathed in plastic above
the capture, wash and release stations. B. A diagrammatic view of MagSweeper cell isolation protocol. C. A controlled shear force produced by the
movement of the magnetic rods in the wash station releases non-specifically bound blood cells. For cells with attached magnetic beads (black
circles), the magnetic rod produces a magnetic force in z proportion to the nonuniformity (dB2/dz) of the magnetic field, thus imparting momentum
in z proportional to (dB2/dz) and to a dwell time that depends both on the sweep speed and on the velocity distribution across the boundary layer
that extends into the fluid from the surface of the sheath, optimizing capture of labeled cells and release of contaminating unlabeled cells. D.
Photomicrograph (200X) of a CTC labeled with 4.5 mm immunomagnetic beads isolated from a patient with metastatic breast cancer. Magnetic beads
are small dark spheres; the CTC appears as a translucent cell surrounded by clusters of beads.
doi:10.1371/journal.pone.0033788.g001
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then screened to eliminate those with poor expression (samples
had to express at least 10 genes). UBB was selected to represent the
most robust reference gene, as reported by Popovici et al. [25]; its
level of expression was associated with overall expression quality in
our sample. EpCAM-captured cells from patient blood samples
with UBB CT .25 were excluded. To identify CTCs, the
EpCAM-captured cells from patient blood samples were further
screened: they had to express both ACTB and GAPDH reference
genes, and at least one of multiple epithelial markers: KRT7,
KRT8, KRT18, and/or KRT19. Cells expressing CD45, a WBC
marker, were excluded.
At this stage, many more CTCs were isolated from some
patients than others. To balance the analysis, at random, samples
were further reduced to select exactly seven cells from each of the
seven cell lines, and at most five cells per patient from the CTCs.
The resulting set of cell lines and CTCs comprised the analysis set
used in statistical summaries and heatmaps. To normalize the
expression, we computed for each sample the mean CT of the
reference panel of UBB, ACTB, and GAPDH. To compute the
normalized expression of a gene in a cell, we took the negative of
the difference between the raw CT expression of the gene in the
sample and the mean reference level in the sample (this is the
negative delta CT). The data was then median centered for each
gene (zero represents the median expression of the gene; positive/
negative values correspond to higher/lower expression respective-
ly).
To produce heatmap images of the data, the expression values
were truncated to a range of +/23 standard deviations of the
centered expression (across all genes); missing values were drawn
in black. To cluster the data, first, missing values were replaced by
plugging in the minimum value of 23 standard deviations,
reflecting the low levels of expression that they represent. Then
standard hierarchical clustering was used with the Euclidean
distance metric. All analyses were performed using R software
version 2.13.1 (http://cran.r-project.org/).
Results
Assay Validation
To test whether sample processing with the MagSweeper itself
altered gene expression profiles, we measured the expression of a
subset of 15 genes in breast cancer cell lines before and after cell
processing. Overall gene expression pattern was not altered during
the labeling or dynamic capture processes of our MagSweeper
isolation protocol, although we noted that even within clonally-
derived cell cultures before processing, some variation exists at the
single cell level (Figure 2A). Moreover, the plating efficiency of
cancer cell lines was similar before and after undergoing magnetic
bead labeling and cell isolation, confirming no discernible effect on
cell viability (Figure 2B).
We next demonstrated that high dimensional single cell analysis
reliably characterizes tumor cells using 96.96 Dynamic Arrays to
measure the expression of 87 cancer-associated and reference
genes in individual cells isolated from primary and metastatic
breast cancer cell lines. This exploratory panel of genes was
selected from the published literature and our previous work in
breast cancer gene expression for their role in molecular pathways
relevant to breast cancer and to represent breast cancer
biomarkers, prognostic markers, and phenotypes associated with
cancer signaling pathways, epithelial-mesenchymal transition
(EMT), cancer stem cells, and metastasis, as well as phenotypes
indicative of contaminating leukocytes (Table S1).
Initially, we tested assay reproducibility for single cell high
dimensional profiling on randomly selected cells from each of
three primary (CCdl054, CCdl672, CCdl675) and four metastatic
breast cancer cell lines (T47D, MCF7, SKBR3, and MDA-MB-
231). Hierarchical clustering was performed with expression data
for 87 selected genes normalized by UBB reference gene
expression for seven single cells from each cell line. We found
that 48/49 cells reproducibly clustered by cell line designation
(Figure 3). Moreover, the profiles of each cell line grouping were
consistent with expected biomarker patterns (e.g., ER, the human
epidermal growth factor receptor 2 [HER2], and the epidermal
growth factor receptor [EGFR], all important biomarkers for
breast cancer prognosis and/or selection of targeted chemother-
apy [26,27]). As expected, the white blood cell marker, CD45 was
not expressed by any of these epithelial cells [28]. Unsupervised
clustering of the cancer cell lines separated ER-negative
(MDA231, SKBR3) apart from ER-positive cell lines (CCdl054,
CCdl672, CCdl675, MCF7, T47D), irrespective of their primary
or metastatic origin. Our single cell expression data here
comprised of an 87-gene set was robust and consistent with
previous clustering patterns of these primary tumor cell lines with
ER-positive metastatic cell lines derived from full scale Affymetrix
array data [20].
Figure 2. Unperturbed gene expression and cell viability of MagSweeper isolated tumor cells. A. Gene expression heat maps of CT
measurements of 15 genes by microfluidic qRT-PCR assays performed on single MCF7 cells before and after labeling and capture by the MagSweeper.
Each gene is measured in triplicate for each single cell. Some single cell expression variation is inherent among individual cells, but the overall pattern
showed no marked effect by our isolation protocol. B. Average plating efficiency (percent of single cells that formed colonies after seven days) of
MCF7 cells; either control, labeled with beads, or labeled and captured by the MagSweeper, performed in triplicate. This demonstrates that cell
viability was not affected by our purification protocol.
doi:10.1371/journal.pone.0033788.g002
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We used the MagSweeper to process blood samples from 45
patients without epithelial cancer: 25 healthy volunteers and 20
lymphoma patients. None had detectable cells in the capture buffer.
CTC Gene Expression Profiling
For cells captured from breast cancer patient blood samples,
gene expression was measured in a total of 510 patient cells
isolated by the MagSweeper. These represented 65 blood samples
from 50 patients: 20 primary breast cancer patients without
detectable metastatic disease, and 30 metastatic breast cancer
patients (Table S2). In this study, we only analyzed cells that
expressed three reference genes (ACTB, GAPDH, UBB).T o
normalize gene expression, we selected the ubiquitin B (UBB)
reference gene whose reliability as a high stability control gene for
qRT-PCR has been validated in a meta-analysis of over 1700
Figure 3. High dimensional analysis of single cells from breast cancer cell lines. A. Heatmap of single cell gene expression of 87 genes
within seven individual cells isolated from three primary tumor-derived (pink: CCdl054, orange: CCdl672, gold: CCdl675), and four metastatic effusion-
derived (red: MDA-231 plum: SKBR3, dark green: MCF7, and bright green: T47D) breast cancer cell lines. Yellow indicates high gene expression; gray is
median expression; blue indicates low expression; and black represents undetectable expression. All cells showed expected expression patterns. The
breast cancer cell lines used represent a spectrum of cell differentiation, e.g., from less differentiated and more mesenchymal/stem cell-like ER-
negative (basal-like) cells (MDA-231 and SKBR3) to more differentiated ER-positive (luminal-like) cells represented by CCdl054, CCdl672, CCdl675,
MCF7, and T47D.
doi:10.1371/journal.pone.0033788.g003
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or weaker expression of ACTB and GAPDH between different
tumors [25]. Thus, we selected cells that strongly expressed UBB at
a threshold of CT ,25 after pre-amplification, assuming that cells
that expressed all three reference genes (ACTB, GAPDH, UBB) and
showed highly robust expression of UBB are less likely to contain
degraded RNA. Sixty-three percent (321/510) of the cells isolated
by the MagSweeper thus qualified for further analysis. From these,
we selected cells that met the following stringent criteria: 1) absent
expression of the leukocyte markers CD45; and 2) expression of
any of the following epithelial markers: KRT7, KRT8, KRT18,
and/or KRT19. Among EpCAM-captured cells with non-degrad-
ed reference gene RNA, 21% also expressed detectable CD45
transcripts; they were designated as white blood cells (WBCs) and
excluded from further analysis. Overall, 60% of cells with non-
degraded reference gene RNA were defined as CTCs. (summa-
rized in Table S3). No EpCAM-labeled epithelial cells were found
in the blood of healthy donors (n=25) or of lymphoma patients
(n=20).
In the hierarchical clustering analysis of CTCs, to avoid
individual patient bias, no more than 5 independent RNA samples
derived from EpCAM-captured KRT+/CD45- cells were analyzed
from the same patient. Thus, the total number of single CTC
profiles inclusive of all subgroups was 105, representing 40 blood
samples from 35 patients –14 with primary breast cancer, and 21
with metastatic breast cancer, and summarized by ER, PR and
HER2 status (Tables S2 and S4).
Thirty-one of the 87 genes evaluated were consistently detectable
in at least 15 percent of the CTCs analyzed. Aside from 3 reference
genes (ACTB, GAPDH, UBB), the remaining 28 genes most
commonly expressed in CTCs represented functional categories
associated with: (1) epithelial phenotype (included in our definition
of CTC) - KRT8, KRT18, KRT19, but also CTNNB1; (2) epithelial
mesenchymal transition (EMT) - TGFß1, FOXC1, CXCR4, NFKB1,
VIM, ZEB2; (3) metastasis - S100A9, NPTN, S100A4; (4) PI3K/
Figure 4. High dimensional single cell analysis and clustering of CTCs isolated from patients with breast cancer. Heatmap of single cell
gene expression for 31-gene subset data derived from 105 CTCs isolated from patients with primary and metastatic breast cancer. Yellow indicates
high gene expression; gray is median expression; blue indicates low expression; and black represents undetectable expression. The samples reveal
two robust clusters for CTCs (lavender: Cluster I; turquoise blue: Cluster II). In addition to epithelial markers, these genes include pathways associated
with EMT, metastasis, and AKT/mTOR signaling.
doi:10.1371/journal.pone.0033788.g004
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apoptosis – BAX, CASP3, CD53, CD59 (6) cell proliferation -
RRM1, MAPK14; (7) DNA repair - PARP1; (8) cell metabolism -
SLC2A1, TFRC; (9) stem cell phenotype - CD24, CD44.
Unsupervised clustering analysis based on the above-mentioned
subset of commonly expressed genes stratified CTCs into: (a)
Cluster I - a relatively small cluster comprised of 21 cells from 13
patients, and (b) Cluster II - a larger cluster comprised of 84 cells
from 30 patients (Figure 4 and Table S4). Whereas reference genes
showed a similar range of variability across CTCs in both clusters,
striking differences were observed for other genes. The majority of
CTCs in Cluster I, as compared to CTCs in Cluster II, showed
stronger expression of S100A9, CD24, VIM, CXCR4, MAPK14,
AKT2, PIK3R1, CTNNB1, CD44, and ZEB2.
A final important observation was that unlike breast cancer cell
lines, CTCs did not cluster by case ID. Eight (23%) cases were
represented in both clusters; 5 cases were exclusive to Cluster I,
and 22 cases to Cluster II (Table S4). Both clusters had similar
proportions of Triple Negative, ER+, and HER2+ tumors.
Differences in median patient age and disease stage (primary vs.
metastatic cancer) were not significant between clusters (Table 1).
Minimal Concurrence between Profiles of CTCs and
Breast Cancer Cell Lines
In an effort to evaluate the similarities between widely used
experimental tumor cell models and patient derived tumor cells, we
combined single cell expression data from primary and metastatic
breast cancer cell lines, and CTC samples towards a clustering
analysis of 154 individual cells. When all 87 test genes were
considered in this comparison, while cell lines and CTCs were
indeed clustered apart, CTC subclassification was not robust, likely
due to a large number of values resulting from undetectable
transcript levels (Figure S1). However, in the analysis of 31 genes
commonly expressed by CTCs, not only was intermixing of CTCs
and single cells of cancer cell lines not observed (with the exception
of 1/84 CTCs from Cluster II), indicating distinctive gene
expression patterns of each tumor cell source, but the distinction
between CTC clusters I and II was maintained relatively
unperturbed. Similarly, the tumor cell lines grouped together, each
with sister cells from the same culture (Figure 5). Phenotypes
underlying such clustering patterns showed that CTCs maintained
higher expression than all tumor cell lines for FOXC1, KRT18,
PTEN,NPTN,TGFß1,KRT8,ZEB2,and CXCR4.Ontheotherhand
all cell lines showed elevated transcript levels for RRM1, AKT1,a n d
AKT2. Rare similarities between experimental and clinical cell
samples included elevated VIM expression in CTCs and ER-
negative cell lines (MDA231 and SKBR3), as well as high S100A9
expression inCTCsandER-positiveprimarybreast cancercell lines
(CCdl054, CCdl672, CCdl675). Overall, expression patterns of
,10% (2/28) common tumor associated gene profiles of CTCs
were recapitulated by a subset of tumor cell line models.
Discussion
Over the past several years, a major factor enabling the
continued characterization of surgically resected tumor tissue is the
highly enriched content of malignant cells in the sample, which
facilitates direct assays on primary tumor cell populations. In
contrast, studying the biology of cells that successfully disseminate
from the primary tumor site requires prior separation from normal
components within patient blood. We have developed a cell
purification technology – the MagSweeper, which gently isolates
rare CTCs with high specificity. Our previous studies have shown
that the MagSweeper can be used reliably to extract functional
human CTCs from the blood of mice implanted with human
tumor xenografts, which retain both their tumor-initiating and
metastasizing capacities [17]. In conjunction with this device, here
we availed recent advances in microfluidics [29], to first report on
high dimensional profiling of single CTCs. We demonstrate that
because our CTC isolation protocol does not impact viability and
RNA integrity of isolated cells nor gene expression [16], and as
evident here by consistent detection of multiple reference gene
transcripts, comprehensive genomic studies on robust subpopula-
tions of cells is greatly facilitated. Using the MagSweeper, our yield
of EpCAM-labeled CTCs from patient blood samples is similar to
previous reports in the literature [6,30].
Analyzing tumor cells by their genomic and transcriptomic
profiles has been an important first step towards understanding
cancer biology. For example, gene expression profiling of primary
tumors and its application in the molecular subtyping of breast
cancer has provided a biological framework for defining the
clinical heterogeneity of this disease. Although an aggressive basal
breast tumor subtype was evident with select biomarkers long
before the advent of genomics [31], comprehensive molecular
signatures of breast cancer revealed myriad gene targets within
such cancers [32]. Similarly, gene expression of disseminated
tumor cells (DTCs) from bone marrow biopsies of breast cancer
patients enabled clustering of different patient samples according
to clinical outcome [33]. However, averaging molecular measure-
ments across ensembles of cells [34–36] – as is also generally
performed in expression analyses of primary or metastatic tumors
[32] – obscures the granularity of individual cell biology and
physiology [37]. And important for high dimensional CTC
analyses (and also dependent on the particular CTC capture
technique used) is addressing the issue of how to eliminate the
contributions of potentially large numbers of contaminating WBCs
to overall gene expression profiles when measuring genes common
to both [14,15]. Isolating CTCs from 10
7 WBCs is a difficult
problem and even techniques that enable 99.9% leukocyte
depletion still show 500–1400 contaminating WBCs following
enrichment [15]. In contrast, 63% of MagSweeper-captured cells
showed robust, non-degraded reference gene expression: of cells
with non-degraded reference RNA, 60% were defined as CTCs
and 21% expressed the CD45 WBC marker. Overall, 38% of
MagSweeper-captured cells (healthy and degraded) fit our robust
definition of a CTC (Table S3). Although we also noted EpCAM-
Table 1. Phenotype of Primary Tumors in CTC Clusters.
CTC
Cluster
Total
cases
Number
of CTCs
Median age at
primary Dx (yrs)
Primary
(%)
Metastatic
(%)
ER or PR- pos
(%)
HER2-pos
(%)
Triple
Negative (%)
I 13 21 43 4/13 (31) 9/13 (69) 6/13 (46) 2/13 (15) 5/13 (38)
II 30 84 45 12/30 (40) 18/30 (60) 12/30 (40) 5/30 (17) 13/30 (43)
doi:10.1371/journal.pone.0033788.t001
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eliminated these unknown cells from our CTC cluster analyses
because they did not fit our stringent definition of a CTC.
However, these cell types may warrant future investigation.
Single cell analysis depicts the true diversity of a heterogeneous
population. We found that single CTCs displayed striking
quantitative variability within a wide spectrum of genes that
would have been obscured by analysis of pooled multiple cells.
These analyses enabled us to identify different CTC subpopula-
tions even within a single blood sample.
It is widely accepted that only a small minority of cells in the
primary tumor are progenitors or ‘‘culprits’’ leading to deadly
metastases. To cure cancer, such culprit cells need to be identified
and characterized for targeted therapy. From the perspective of
patient care, CTC biology may be more pertinent than primary
tumor biology because some CTCs may follow paths to future
metastatic seeding or home to specific metastatic sites. Profiling
CTCs specifically refines analyses of those cells capable of entering
blood vessels and surviving within the vasculature. In our study,
the extracted CTCs were almost exclusively Triple Negative
(lacking ER, PR,o rHER2 expression – Figure S1), whether or not
the primary tumors of those patients displayed this phenotype
(Table S2). Triple Negative tumors are aggressive and associated
with higher metastatic potential, shorter time to metastasis and
have limited targeted treatment options [32,38,39]. Others have
employed CTCs in cell-by-cell qualitative studies, or low
dimensional quantitative analyses for the phenotypes of this breast
cancer subtype. Using indirect immunolocalization and fluores-
cent in situ hybridization (FISH), Meng et al. showed that
individual tumor cells in 12 primary breast cancers, and matched
CTCs either expressed HER2, urokinase plasminogen activator
receptor (uPAR), both, or neither [40], exemplifying CTC
heterogeneity at the single cell level. Significant discordances
between ER, PR, and/or HER2 status among enriched pooled
CTCs and corresponding primary tumors have been observed in
patients with primary and metastatic breast cancers [41–45], and
Figure 5. Combined breast cancer cell line and CTC clusters. Heatmap of single cell gene expression for 31-gene subset data derived from
seven breast cancer cell lines and 105 CTCs isolated from patients with primary and metastatic breast cancer. Yellow indicates high gene expression;
gray is median expression; blue indicates low expression; and black represents undetectable expression. The samples reveal two robust clusters for
CTCs (lavender: Cluster I; turquoise blue: Cluster II) and two clusters representing primary (pink: CCdl054, orange: CCdl672, gold: CCdl675) and
metastatic cell lines. Note dendrogram branches that cluster ER-negative cell lines (red: MDA-231; plum: SKBR3) and ER-positive cell lines (dark green:
MCF7, and bright green: T47D).
doi:10.1371/journal.pone.0033788.g005
Single Cell Analysis of Circulating Tumor Cells
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e33788may lead to clinical trials testing CTC biomarkers rather than
strict reliance on primary tumor biomarkers for the selection of
targeted therapies. Loss of expression of ER/PR/HER2 in CTCs
noted in our particular patient samples could explain why
therapies that target these biomarkers may fail to control end-
stage disease; confirmation would require biopsies of late-stage
metastases. Although CTC heterogeneity between patients is well
recognized [46], an important finding in our study was that
individual CTCs did not cluster by patient or disease stage
(primary cancer vs. metastatic cancer), which again supports the
concept that these cells belong to subpopulations with phenotypes
fundamentally different from pooled tumor tissue, and that
studying and phenotyping the primary tumor alone may lead to
suboptimal treatment selection.
The demonstration of numerical/quantitative associations
between CTCs and clinical outcome in previous studies
[5,47,48], albeit limited in terms of guiding molecular target
based therapeutics, is indeed supportive of the hypothesis that
CTCs, as a whole represent the culprit cells that lead to patient
demise. Thus the simultaneous pursuit of multiple targeting
strategies identified by high dimensional profiling for the
elimination of all observed CTC subpopulations is warranted.
Our gene expression data display CTC stratification into the
major Clusters I and II, comprised of strongly and weakly
expressing cells, respectively. In both clusters, robust expression of
metastasis associated genes, such as NPTN, S100A4, and S100A9
was striking. Notable in particular was expression of genes such as
VIM, TGFß1, ZEB2, FOXC1, and CXCR4, associated with the
induction and maintenance of EMT, a process by which epithelial
cells transition to a more mesenchymal phenotype, both morpho-
logically and biochemically [49–56], thereby increasing cell
invasiveness and the link to cancer progression and poor prognosis
[56,57]. That the CTCs in Cluster II generally showed low to
undetectable values for the vast majority of test transcripts suggests
that characterization of this cluster could be improved further by
including additional genes. Intriguingly, high levels of PTEN
expression in 83% of the CTCs were observed despite the known
inverse association between this gene and TGFb expression
[58,59]. It is possible that repression of this gene by TGFb
requires receptor tyrosine kinase signaling (such as EGFR) [60],
which might be compromised as indicated by undetectable EGFR
expression in the CTCs in our study (Figure S1). Consistent with
the acquisition of invasive and migratory characteristics is the
absence of the cell adhesion protein, CDH1, in migrating cells [57]
such as CTCs, as illustrated by our expression data. Ostensibly,
systematic implementation of single cell CTC profiling will shed
new light on the dynamics of migratory tumor cell biology during
metastatic dissemination.
Identifying metastatic cell diversity through CTC profiling
could more effectively guide drug selection in late stage cancer
patients, making it reasonable to speculate that patients whose
blood contains CTCs with these diverse phenotypes could
greatly benefit from optimized multidrug treatment regimens.
Therapy that targets only one CTC population might not
ablate other subpopulations, which may continue to spread
and grow. High transcript levels of genes most commonly
expressed in CTCs suggest valuable targeting opportunities
prior to metastatic seeding. The finding of overexpression of a
metastasis-associated calcium- and zinc-binding protein en-
coding gene - S100A9 [61] in CTCs suggests a valid targeting
opportunity, demonstrated previously for another member of
this family - S100P, in aggressive breast cancer cells [20]. As
t h ep h e n o t y p e so fC T C sc o n t i n u et ob er e v e a l e dr e l i a b l ya n d
reproducibly in the future, it will be important to evaluate their
functional response to putative druggable targets based on the
biology reflected in relevant preclinical models. By including
seven independent breast cancer cell line models in our single
cell profiling studies, significant differences between these and
CTCs could be determined. For example: (a) CTCs main-
tained higher expression than all tumor cell lines for FOXC1,
KRT18, PTEN, NPTN, TGFß1, KRT8, ZEB2, and CXCR4;( b )
cancer cell lines displayed measurable CDH1 expression, but
only 2/105 CTCs expressed transcripts for this epithelial cell
adhesion protein that is down-regulated in EMT; and (c) all
single cells within cancer cell lines of known molecular
subtypes maintained ER, PR, EGFR,a n dHER2 expression,
whereas only 1, 1, 1, and 6/105 CTCs, respectively, displayed
these clinically-informative phenotypes. Thus, the careful
selection of appropriate experimental systems, and/or new
developments will be necessary in this regard.
Our expression profiling analyses demonstrated that CTC
populations are relatively quiescent. Transcript levels of growth
factors and their receptors, such as VEGFA, MET, ESR1, EGFR,
and HER2 were relatively undetectable in CTCs compared to
cancer cell lines. Consequently, expression of downstream effectors
involved in cell cycle progression and proliferation such as MYC,
ATF3, TERT, RAC1, FOXA1, RRM1, CCNB1, and BIRC5 were
significantly diminished in CTCs in contrast to breast cancer cell
lines. Thus, conventional therapies targeted at proliferating cells
may be inadequate for eliminating metastatic seeding by CTCs.
On the other hand, we found that some CTCs maintained the
expression of genes associated with the PI3K-AKT-mTOR cell
survival pathway. This is significant from a clinical perspective
because there are multiple new drugs under development or in
early clinical trials that target this pathway [62]. By including such
CTC analysis for patients entering these trials, a companion
diagnostic for predicting those who may respond to these drugs
could be explored. Overall, detectable variations in gene
expression provide an opportunity for further fine-tuning towards
more personalized approaches of targeting specific overexpressed
gene products and activated pathways. Most importantly, the ease
of liquid biopsies would allow optimized and timely decisions for
therapeutic intervention.
Supporting Information
Figure S1 Cluster analysis of full multiplexed gene
expression dataset in breast cancer cell lines and
patient CTCs. Heatmap of single cell expression for 87-gene
profiles of 254 single cells derived from seven replicates each of
seven breast cancer cell lines and 105 CTCs isolated from
patients with primary and metastatic breast cancer. Yellow
indicates high gene expression; blue indicates low expression; and
black represents undetectable expression. The cancer cell lines
(olive) cluster apart from the CTCs (brown) due to distinct
differences in expression profiles. There was far greater similarity
between all CTCs than with routinely used breast cancer cell
lines.
(TIF)
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Table S3 MagSweeper-captured single cells from
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